Brief: Biosergen Q4 EBITDA SEK -12.49 Million
10/02/2026 07:30
Feb 10 (Reuters) - Biosergen Q4 net income SEK -12.463 million. Q4 EPS SEK -5.31
Recent news on Biosergen AB
See all newsBrief: Nasdaq Approves Biosergen's Delisting Application
Brief: Biosergen Applies For Delisting Of The Company's Shares From Nasdaq First North Growth Market Conditional Upon Completion Of The Merger With Flerie
Brief: Biosergen Resolves On Set-Off Issue
Brief: Biosergen Rights Issue Oversubscribed
Brief: Biosergen Reports H1 EBITDA Of SEK -10.5 Million